October 20, 2014 / 2:26 PM / 3 years ago

Valeant CEO sees revised Allergan bid worth more than $200 per share

J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec May 20, 2014. REUTERS/Christinne Muschi

(Reuters) - Valeant Pharmaceuticals Inc (VRX.TO) Chief Executive Michael Pearson said in an interview with Reuters on Monday that he is confident a revised bid for Allergan Inc (AGN.N) will be worth over $200 per share, once Valeant’s stock rises and with cash added to the offer.

Pearson said Valeant could make a revised offer at any time and that the company’s stock has been hurt by Allergan’s criticism and uncertainty about whether a deal will get done. Valeant’s offer is currently worth about $176 per share.

Reporting by Rod Nickel in Winnipeg, Manitoba; Editing by Chizu Nomiyama

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below